Your browser doesn't support javascript.
loading
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.
Ali, H R; Dariush, A; Thomas, J; Provenzano, E; Dunn, J; Hiller, L; Vallier, A-L; Abraham, J; Piper, T; Bartlett, J M S; Cameron, D A; Hayward, L; Brenton, J D; Pharoah, P D P; Irwin, M J; Walton, N A; Earl, H M; Caldas, C.
Afiliação
  • Ali HR; Li Ka Shing Centre, Cancer Research UK Cambridge Institute.
  • Dariush A; Department of Pathology.
  • Thomas J; Institute of Astronomy, University of Cambridge, Cambridge.
  • Provenzano E; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh.
  • Dunn J; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge.
  • Hiller L; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Vallier AL; Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge.
  • Abraham J; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Piper T; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Bartlett JMS; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge.
  • Cameron DA; Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge.
  • Hayward L; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge.
  • Brenton JD; Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge.
  • Pharoah PDP; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh.
  • Irwin MJ; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh.
  • Walton NA; Ontario Institute for Cancer Research, Toronto, Canada.
  • Earl HM; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh.
  • Caldas C; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh.
Ann Oncol ; 28(8): 1832-1835, 2017 Aug 01.
Article em En | MEDLINE | ID: mdl-28525534
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Linfócitos / Protocolos de Quimioterapia Combinada Antineoplásica / Linfócitos do Interstício Tumoral / Biologia Computacional / Terapia Neoadjuvante / Bevacizumab Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Linfócitos / Protocolos de Quimioterapia Combinada Antineoplásica / Linfócitos do Interstício Tumoral / Biologia Computacional / Terapia Neoadjuvante / Bevacizumab Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article